Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content

Table 2 The relationship between HPV integration type and CIN2 + risk in each HPV integration reads strata

From: HPV integration status conversion and CIN2 + cancer risk stratification based on HPV integration levels among HPV integration-positive women: a 1-year follow-up study

HPV integration reads

Women No. (%)

P value

Total

(N = 181)

Non-HPV16/18 integration

(n = 64)

HPV16/18 integration

(n = 117)

6–20

69 (38.1)

43 (67.2)

26 (22.2)

-

 Immediate CIN2+

25 (36.2)

13 (30.2)

12 (46.2)

0.206

 1-year cumulative CIN2+

27 (39.1)

14 (32.6)

13 (50.0)

0.204

21–40

16 (8.8)

3 (4.6)

13 (11.1)

-

 Immediate CIN2+

10 (62.5)

2 (66.7)

8 (61.5)

> 0.99

 1-year cumulative CIN2+

11 (68.8)

2 (66.7)

9 (69.2)

> 0.99

41–200

35 (19.3)

5 (7.8)

30 (25.6)

-

 Immediate CIN2+

30 (85.7)

3 (60.0)

27 (80.0)

0.139

 1-year cumulative CIN2+

31 (88.6)

4 (80.0)

27 (80.0)

0.477

201–1000

29 (16.0)

6 (9.4)

23 (19.7)

-

 Immediate CIN2+

28 (96.6)

6 (100.0)

22 (95.7)

> 0.99

 1-year cumulative CIN2+

28 (96.6)

6 (100.0)

22 (95.7)

> 0.99

> 1000

32 (17.7)

7 (11.0)

25 (21.4)

-

 Immediate CIN2+

30 (93.8)

7 (100.0)

23 (92.0)

> 0.99

 1-year cumulative CIN2+

31 (96.9)

7 (100.0)

24 (96.0)

> 0.99

  1. Abbreviations: CIN2+, cervical intraepithelial neoplasia grade 2 or worse; HPV, Human papillomavirus
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us